Taiwan Chih-Kung Lee, Minister of Economic Affairs of the Republic of China (Taiwan) provides insights into Taiwan’s “new economic model” recently established by the new government to boost the country’s economic growth and ensure Taiwan renews its role as an innovation pioneer. He also documents the crucial role that the pharmaceutical…
Taiwan Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of the corporate world. You became head of Taiwan’s Development Center for Biotechnology after having held prestigious positions in the US…
Taiwan Thomas Yuan, the CEO of TFBS Bioscience, documents the tailored added-value that this fast-growing product testing company strives to bring to emerging pharmaceutical and biotech companies in the Asia Pacific region, while TFBS already stands out as the only service provider of its kind in Taiwan and one of the…
Switzerland How would you present the strengths of the Lake Geneva region’s strengths to our international audience? The Lake Geneva region, which we often call the ‘health valley of Switzerland’, benefits from having two intersecting innovative clusters, one in MedTech and another in biotech. Looking at the course of life sciences…
Pharma 2016 has been a great year for PharmaBoardroom, with interviews from global CEOs and ministers, groundbreaking country reports on some of the world’s key pharma markets, and insightful articles which get to the heart of the sector’s key issues. Stay tuned in 2017 for more of the same! INTERVIEWS OF…
Ireland Frederic Secail, General Manager of Servier’s second strategic and international production facility within Servier Industry, located in Arklow, Ireland, outlines his ambitious transformation program, Arklow 2020, to anticipate and prepare the site for the future. You have been GM of Servier’s Arklow facility since 2013. What was the mandate given…
Ireland James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for ultra-rare diseases, the main challenge he sees for BioMarin’s international operations, and his priorities for the next few years. James,…
Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development. Switzerland of course has quite the reputation as a hub for biotech activity – how…
Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…
Switzerland Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region. Since day one, Alexion’s mission has been to focus solely on discovering treatments for patients affected by these incredibly rare…
Mexico Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to further accelerate the growth and consolidate the strategic positioning of Shire, a company that now proudly stands out as the…
Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…
See our Cookie Privacy Policy Here
